Trial Profile
Trabectedin Combined With Regional Hyperthermia as Second Line Treatment for Adult Patients With Advanced Soft-tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms HyperTET
- 27 Feb 2023 Planned End Date changed from 1 Jul 2022 to 1 Aug 2023.
- 27 Feb 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Aug 2023.
- 27 Feb 2023 Status changed from recruiting to active, no longer recruiting.